[ARS] GRI Bio, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

ARS

07/11/2025 - 04:20 PM

ARS - GRI Bio, Inc.

ARS Filing - GRI Bio, Inc.

This filing is available as a PDF document.

Filing Type: ARS

Company: GRI Bio, Inc. (GRI)

Acceptance Date: 2025-07-11T16:20:46.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

GRI Bio

NASDAQ:GRI

GRI Rankings

#6813 Ranked by Market Cap

N/A Ranked by Dividends

GRI Latest News

Jan 21, 2026

GRI Bio Announces Reverse Stock Split

Jan 8, 2026

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

Dec 12, 2025

GRI Bio Announces Closing of $8.0 Million Public Offering

Dec 11, 2025

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Dec 10, 2025

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Latest SEC Filings

Jan 21, 2026

[8-K] GRI Bio, Inc. Reports Material Event

Jan 8, 2026

[8-K] GRI Bio, Inc. Reports Material Event

Jan 9, 2026

[424B5] GRI Bio, Inc. Prospectus Supplement (Debt Securities)

Jan 9, 2026

[8-K] GRI Bio, Inc. Reports Material Event

Jan 15, 2026

[8-K] GRI Bio, Inc. Reports Material Event

GRI Stock Data

Market Cap 2.95M

Float 12.42M

Insiders Ownership 0.02%

Institutions Ownership 0.78%

Short Percent 2.01%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City LA JOLLA